Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus PHENYLBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus PHENYLBUTAZONE.
DYLOJECT vs PHENYLBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Category C
Category C
NSAID
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."